Colombia vs Kazakhstan: Average cost of drugs for extensively drug-resistant tuberculosis
Colombia
5,370 constant 2022 US$
in 2024
Kazakhstan
6,329 constant 2022 US$
in 2023
Colombia rank
8th
Kazakhstan rank
5th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Colombia
- Kazakhstan
How they compare
Kazakhstan currently reports 6,329 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia, a difference of 959 constant 2022 US$.
That makes Kazakhstan's figure about 1.2 times Colombia's.
Across all 5 years both countries report, Kazakhstan has been ahead every year.
Colombia ranks 8th and Kazakhstan ranks 5th of 56 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Colombia | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,800 constant 2022 US$ | 4,830 constant 2022 US$ | 2,030 constant 2022 US$ | Kazakhstan |
| 2020s | 730 constant 2022 US$ | 4,806 constant 2022 US$ | 4,076 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Colombia or Kazakhstan?
- Kazakhstan, at 6,329 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Colombia and Kazakhstan?
- 959 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Colombia and Kazakhstan?
- 5 years are reported by both, from 2019 to 2023.
- How do Colombia and Kazakhstan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Colombia ranks 8th and Kazakhstan ranks 5th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.